Trials / Completed
CompletedNCT00291187
VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 411 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 21 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 20 mg VEC-162 | 20 mg VEC-162 |
| DRUG | 50 mg VEC-162 | 50 mg VEC-162 |
| DRUG | 100 mg VEC-162 | 100 mg VEC-162 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2006-02-13
- Last updated
- 2014-10-15
- Results posted
- 2014-10-15
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00291187. Inclusion in this directory is not an endorsement.